A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: Advantages of pathway-based discovery

被引:27
|
作者
Hellerstein, Marc K. [1 ,2 ,3 ]
机构
[1] Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA
[2] Univ Calif San Francisco, Dept Med, Div Endocrinol & Metab, San Francisco, CA 94110 USA
[3] KineMed Inc, Emeryville, CA 94608 USA
关键词
Drug discovery and development; Pathway-based discovery; Metabolic flux analysis; Exploiting complexity;
D O I
10.1016/j.ymben.2007.09.003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Contemporary drug discovery and development (DDD) is dominated by a molecular target-based paradigm. Molecular targets that are potentially important in disease are physically characterized; chemical entities that interact with these targets are identified by ex vivo high-throughput screening assays, and optimized lead compounds enter testing as drugs. Contrary to highly publicized claims, the ascendance of this approach has in fact resulted in the lowest rate of new drug approvals in a generation. The primary explanation for low rates of new drugs is attrition, or the failure of candidates identified by molecular target-based methods to advance successfully through the DDD process. In this essay, I advance the thesis that this failure was predictable, based on modern principles of metabolic control that have emerged and been applied most forcefully in the field of metabolic engineering. These principles, such as the robustness of flux distributions, address connectivity relationships in complex metabolic networks and make it unlikely a priori that modulating most molecular targets will have predictable, beneficial functional outcomes. These same principles also suggest, however, that unexpected therapeutic actions will be common for agents that have any effect (i.e., that complexity can be exploited therapeutically). A potential operational solution (pathway-based DDD), based on observability rather than predictability, is described, focusing on emergent properties of key metabolic pathways in vivo. Recent examples of pathway-based DDD are described. In summary, the molecular target-based DDD paradigm is built on a naive and misleading model of biologic control and is not heuristically adequate for advancing the mission of modern therapeutics. New approaches that take account of and are built on principles described by metabolic engineers are needed for the next generation of DDD. (C) 2007 Published by Elsevier Inc.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [31] Target-based drug discovery: Applications of fluorescence techniques in high throughput and fragment-based screening
    Kumar, Vikrant
    Lakshman, Puneeth Kumar Chunchagatta
    Prasad, Thazhe Kootteri
    Manjunath, Kavyashree
    Bairy, Sneha
    Vasu, Akshaya S.
    Ganavi, B.
    Jasti, Subbarao
    Kamariah, Neelagandan
    HELIYON, 2024, 10 (01)
  • [32] Nano-quantum sensors-based imaging and sensing for target-based drug discovery and development
    Shimada, Taisuke
    Ueda, Yasuyuki
    Takemaru, Hikari
    Baba, Yoshinobu
    Yukawa, Hiroshi
    TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2024, 171
  • [33] In silico tools used for compound selection during target-based drug discovery and development
    Caldwell, Gary W.
    EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (08) : 901 - 923
  • [34] Harnessing the Versatility of Optical Biosensors for Target-Based Small-Molecule Drug Discovery
    Kaminski, Tim
    Gunnarsson, Anders
    Geschwindner, Stefan
    ACS SENSORS, 2017, 2 (01): : 10 - 15
  • [35] Weak links: Advancing target-based drug discovery by identifying the most vulnerable targets
    Bosch, Barbara
    Dejesus, Michael A.
    Schnappinger, Dirk
    Rock, Jeremy M.
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2024, 1535 (01) : 10 - 19
  • [36] Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines
    Swinney, D. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (04) : 299 - 301
  • [37] Designing innovative therapies for neuropathic pain: pros and cons of target-based drug discovery
    Inglese, J.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2014, 19 : S6 - S9
  • [38] A Structure-Based Drug Discovery Paradigm
    Batool, Maria
    Ahmad, Bilal
    Choi, Sangdun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (11)
  • [39] Target-based discovery of therapeutic agents from food ingredients
    Shiuan, David
    Tai, Da-Fu
    Huang, Kao-Jean
    Yu, Zhipeng
    Ni, Feng
    Li, Jianrong
    TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2020, 105 : 378 - 384
  • [40] Comment on: Target-based discovery of a broad-spectrum flukicide
    Tripathi, Timir
    PLOS NEGLECTED TROPICAL DISEASES, 2024, 18 (11):